Titan Spine has signed a distribution agreement with Biomet to bring Titan Spine’s line of Endoskeleton interbody fusion devices to Germany.
“Biomet is not only a leader in global spine technology, it shares our philosophy that titanium and engineered surface technology can be used to enhance fusion and bone growth upon implantation of interbody fusion devices, leading to improved patient outcomes,” Kevin Gemas, president of Titan Spine, stated in a company press release. “We are pleased to enter into this partnership with Biomet with the goal of bringing Titan Spine devices to more physicians and patients in Europe.”
Titan Spine will provide its Endoskeleton interbody fusion devices to Biomet for distribution in Germany, and the companies are also considering bringing the Endoskeleton line to other countries in the European Union.
The implant surface technology of the Endoskeleton interbody fusion device consists of roughened topographies at the macro, micro and cellular levels. The combination of surface levels is designed to promote new bone growth, encourage natural production of new bone morphogenetic proteins and create a faster fusion process.